(Q36920649)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722967%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722967%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722967%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Robin E Buckingham

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722967%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

1 reference

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722967%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722967%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722967%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722967%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

741-753

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722967%20AND%20SRC:MED&resulttype=core&format=json

Loop diuretics: from the Na-K-2Cl transporter to clinical use.

4 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200730090-00002

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

12 December 2020

B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells

1 reference

12 December 2020

Insulin resistance and risk of congestive heart failure

1 reference

12 December 2020

Effect of various diuretic treatments on rosiglitazone-induced fluid retention.

1 reference

12 December 2020

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

1 reference

12 December 2020

Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up

1 reference

12 December 2020

SGK integrates insulin and mineralocorticoid regulation of epithelial sodium transport

1 reference

12 December 2020

Impact of obesity on plasma natriuretic peptide levels

1 reference

12 December 2020

Glycemic control and heart failure among adult patients with diabetes

1 reference

12 December 2020

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project

1 reference

12 December 2020

Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.

1 reference

12 December 2020

The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.

1 reference

12 December 2020

Childhood adiposity as a predictor of cardiac mass in adulthood: the Bogalusa Heart Study

1 reference

12 December 2020

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

1 reference

12 December 2020

Diabetic macular edema associated with glitazone use.

1 reference

12 December 2020

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes

1 reference

12 December 2020

Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy

1 reference

12 December 2020

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

1 reference

12 December 2020

Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects

1 reference

12 December 2020

Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.

1 reference

12 December 2020

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

1 reference

12 December 2020

Amiloride and its analogs as tools in the study of ion transport

1 reference

12 December 2020

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

12 December 2020

Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255

1 reference

12 December 2020

Thiazide diuretic effect on medullary collecting duct function in the rat

1 reference

12 December 2020

Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus

1 reference

12 December 2020

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

1 reference

12 December 2020

Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.

1 reference

12 December 2020

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

1 reference

12 December 2020

The edematogenic properties of insulin

1 reference

12 December 2020

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

12 December 2020

PPARgamma agonists do not directly enhance basal or insulin-stimulated Na(+) transport via the epithelial Na(+) channel

1 reference

12 December 2020

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

1 reference

12 December 2020

Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus

1 reference

12 December 2020

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

1 reference

12 December 2020

The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment

1 reference

12 December 2020

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

1 reference

12 December 2020

Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissuein Vivoin Patients with Type 2 Diabetes

1 reference

12 December 2020

Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors

1 reference

12 December 2020

Thiazolidinedione-associated congestive heart failure and pulmonary edema

1 reference

12 December 2020

Role of diabetes in congestive heart failure: the Framingham study

1 reference

12 December 2020

Pivotal role of peroxisome proliferator-activated receptor gamma (PPARgamma) in regulation of erythroid progenitor cell proliferation and differentiation

1 reference

12 December 2020

Troglitazone and liver injury: in search of answers

1 reference

12 December 2020

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

12 December 2020

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

12 December 2020

Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?

1 reference

12 December 2020

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

1 reference

12 December 2020

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

12 December 2020

Pioglitazone initiation and subsequent hospitalization for congestive heart failure

1 reference

12 December 2020

Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure

1 reference

12 December 2020

Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione

1 reference

12 December 2020

Expression of peroxisome proliferator-activated receptor-gamma1 and peroxisome proliferator-activated receptor-gamma2 in visceral and subcutaneous adipose tissue of obese women

1 reference

12 December 2020

Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet

1 reference

12 December 2020

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

1 reference

12 December 2020

B-type natriuretic peptide levels in obese patients with advanced heart failure

1 reference

12 December 2020

Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians

1 reference

12 December 2020

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

1 reference

12 December 2020

Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

1 reference

12 December 2020

The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein

1 reference

12 December 2020

Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure

1 reference

12 December 2020

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

12 December 2020

Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus

1 reference

12 December 2020

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

12 December 2020

1 reference

12 December 2020

Obesity and the risk of heart failure

1 reference

12 December 2020

Thiazolidinediones and congestive heart failure-exacerbation or new onset of left ventricular dysfunction?

1 reference

12 December 2020

Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis

1 reference

12 December 2020

Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study.

1 reference

12 December 2020

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

12 December 2020

Thiazolidinedione use and bone loss in older diabetic adults

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

Thiazolidinedione-induced edema

1 reference

12 December 2020

Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.

1 reference

12 December 2020

PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells

1 reference

12 December 2020

Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration

1 reference

12 December 2020

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

1 reference

12 December 2020

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

12 December 2020

Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

1 reference

12 December 2020